ライフサイエンスコーパス: embolus

1 ad cycle 1 dose-limiting toxicity (pulmonary embolus).

2 thmia, symptomatic hypotension, or pulmonary embolus).

3 osis type (deep vein thrombosis or pulmonary embolus).

4 No patient developed a pulmonary embolus.

5 and its 360 degrees distribution around the embolus.

6 ent as a result of an asymptomatic pulmonary embolus.

7 cause serious conditions due to paradoxical embolus.

8 leak, small bowel obstruction, and pulmonary embolus.

9 during treatment as a result of a pulmonary embolus.

10 cyst and accounts for the compactness of the embolus.

11 n conduit/right atrial thrombus or pulmonary embolus.

12 3% of patients having a stroke or peripheral embolus.

13 ent required surgery for a delayed popliteal embolus.

14 echniques permit direct visualization of the embolus.

15 gnant patients suspected of having pulmonary embolus.

16 ient ischemic attack, and 1 had a peripheral embolus.

17 as a result of sepsis and one of a pulmonary embolus.

18 One death occurred related to a pulmonary embolus (0.4%).

19 fic diseases, RRs were as follows: pulmonary embolus 1.87 (95% CI 1.13-3.07, p=0.01 [including 0.2% m

20 Grade 4 adverse events included pulmonary embolus (1), vomiting and constipation (1), and proteinu

21 mA; 0.35-second tube rotation) and pulmonary embolus (64 sections at 1.25 mm, 140 kVp, 645 mA, 0.5-se

22 tients, V-P scintigrams predicted unilateral embolus; 64 patients underwent pulmonary angiography of

23 the proportion of patients with new cerebral embolus after TAVR and to investigate whether parenteral

24 (VTE) (deep venous thrombosis and pulmonary embolus) after splenectomy was 4.3% compared with 1.7% i

25 Two patients had a pulmonary embolus and four had Greenfield filters in the remote pa

26 n thrombosis but a reduced rate of pulmonary embolus and heparin-induced thrombocytopenia among criti

27 ings were driven by lower rates of pulmonary embolus and heparin-induced thrombocytopenia and corresp

28 enerates the formation of the lymphovascular embolus and is responsible for its unique properties of

29 le-out' for myocardial infarction, pulmonary embolus, and aortic dissection, with an eye to improving

30 , sequelae of gastric perforation, pulmonary embolus, and disease progression.

31 Chest pain, pulmonary embolus, and mental status change cases posed the greate

32 Chest pain, pulmonary embolus, and mental status change cases posed the greate

33 ombus, ischemic stroke, or systemic arterial embolus; and nonsystemic TEC, defined as Fontan conduit/

34 Patients with amniotic fluid embolus are best managed using a multidisciplinary appro

35 nique properties of the lymphovascular tumor embolus are poorly understood largely because of the abs

36 iagnosis in 15 cases, with the most proximal embolus at the segmental level in four cases and at the

37 re calculated for each MR technique on a per-embolus basis, and 95% confidence intervals were calcula

38 Embolus detection rates were lowest in the lingula branc

39 evaluation, daily transcranial Doppler with embolus detection studies, and neurological examinations

40 l charts were reviewed for demographic data, embolus detection, and outcomes up to 2 years after the

41 lpha2-antiplasmin inactivation, causing more embolus dissolution than clinical-dose r-tPA alone (P<0.

42 mbosis not otherwise specified, or pulmonary embolus during the study period, and who had been treate

43 However, within the lymphovascular embolus, E-cad and its proteolytic processing by calpain

44 The rate of embolus extravasation was significantly decreased by pha

45 us studies, demonstrated that the tumor cell embolus (IBC spheroid) forms on the basis of an intact a

46 roaches (H-2K(d)-E-cad), that the tumor cell embolus (IBC spheroid) forms on the basis of an intact a

47 The tumor cell embolus (IBC spheroid), in contrast, fails to bind the s

48 Evidence of an embolus in a main pulmonary or lobar artery or evidence

49 ne death despite treatment and one recurrent embolus in a nontreated patient.

50 an extra breast cancer,stroke, or pulmonary embolus in about 6 per 1000 users aged 50-59 and 12 per

51 and non-lethal means to assess for pulmonary embolus in the non-human primate.

52 nt expired as a result of an acute pulmonary embolus in the setting of bilateral hip fractures.

53 The MCA was occluded by an embolus in Wistar rats (n = 71).

54 intracranial haemorrhages, and one systemic embolus) in people assigned to warfarin and 48 primary e

55 The lymphovascular tumor embolus is a blastocyst-like structure resistant to chem

56 e, comorbidity, and surgical risk (pulmonary embolus, leak, death, incisional hernia) than in other p

57 s were limited to clinically unimportant air embolus (n = 2).

58 of platelet accumulation at the site of the embolus occluding the MCA and within downstream cerebral

59 in PAI-1 immunoreactivity at the site of the embolus occluding the MCA were detected 1 h (n=7) and 4

60 were subjected to variable MCAO by suture or embolus occlusion.

61 ression in the genesis of the lymphovascular embolus of IBC.

62 ations OR 0.72 (95% CI 0.55-0.93), pulmonary embolus OR 0.29 (95% CI 0.11-0.73), pneumonia OR 0.66 (9

63 or laceration (APL), postoperative pulmonary embolus or deep venous thrombosis (PEDVT), foreign body

64 farction, peripheral or pulmonary thrombosis/embolus, or heart failure.

65 roke, transient ischemic attack, or systemic embolus (p = 0.014) were positive predictors of warfarin

66 n thrombosis (DVT) alone in 49.7%, pulmonary embolus (PE) alone in 25.4%, DVT plus PE in 13.6%, arter

67 Pulmonary embolus (PE) was identified in 44 recipients (incidence,

68 nterpretation algorithms for acute pulmonary embolus (PE).

69 xtender rounds reduces the risk of pulmonary embolus, pneumonia, and death when compared to chart doc

70 e adverse events (including death, pulmonary embolus, pneumonia, deep wound infection, and acute myoc

71 clinical scenarios: postoperative pulmonary embolus, pneumothorax, myocardial infarction, gastrointe

72 perioperative death included leak, pulmonary embolus, preoperative weight, and hypertension.

73 dies examined deep vein thrombosis/pulmonary embolus prevention (42%) or venous ulceration (25%).

74 The Multi Mechanical Embolus Removal in Cerebral Ischemia trial showed that g

75 of detached biofilm particles depends on the embolus size and could be attributed to nutrient-limited

76 rived for each set of images on the basis of embolus size and location.

77 3 days after surgery, following a pulmonary embolus (spleen weight 500 g, mortality 1/108, 0.9%).

78 Major complications (reintubation, pulmonary embolus, stroke, renal failure, coma, cardiac arrest, my

79 allows more confident detection of pulmonary embolus than does CFA, with no loss in diagnostic accura

80 culty with rapidly adequately diagnosing the embolus, the lack of good data supporting the use of thr

81 bedside echocardiogram suggesting pulmonary embolus, thrombolytic therapy was administered during ca

82 nd the apparent lack of binding of the tumor embolus to the surrounding endothelium.

83 Iodine-123-bitistatin had embolus-to-blood ratios averaging 27 +/- 7, which was hi

84 ined) were cellulitis (two cases), pulmonary embolus (two cases), and deep-vein thrombosis (three cas

85 lopment of deep vein thrombosis or pulmonary embolus (venous thromboembolism [VTE]).

86 Pulmonary embolus was diagnosed in 357 patients (24.9%).

87 An embolus was found in all rats at 24 h after embolization

88 Pulmonary embolus was not suspected at CT in the remaining 18 pati

89 gnant patients suspected of having pulmonary embolus, with considerable variability in their policies